ESTRO 2025 - Abstract Book

S4139

RTT - Patient care, preparation, immobilisation and IGRT verification protocols

ESTRO 2025

The oncologist delineates the treatment area; a plastic-coated wire is applied to the delineated area. A 1-minute 3D scan using Einstar technology captures the region of interest (ROI), which is processed with Exstar and Ideamaker software. The 3D print of the ROI is created. The lead is moulded to the 3D print with the aperture matching the delineated region. The patient attended for a lead mask fitting prior to the treatment start date.

The 3D print pathway was evaluated against the traditional pathway in terms of accuracy, resource utilisation and efficiency. A short questionnaire was also conducted to asses staff views of on the pathway.

Results: From the 33 patients, 14 (42%) required minor adjustments (<2mm) at fitting appointment; while 19 (58%) had no adjustments. This is a significant improvement compared to traditional pathway which required 10% minor and 50% major adjustments over a preceding 10 month period.

The 3D print pathway reduced fabrication time by 75 minutes, improving capacity for two additional mould room slots and saving £50 in staff costs per patient.

Patient experience also improved, with the average mould room appointment time reduced by 45 minutes compared to the traditional pathway. Feedback from the multi-disciplinary team was highly supportive of the 3D print pathway as an alternative.

Conclusion: Integrating 3D printing technology for lead mask fabrication in electron radiotherapy is a promising advancement in treating NMSC on the face. This approach offers a personalised, precise, and patient-friendly alternative to traditional methods, setting a new standard in radiotherapy for NMSC and potentially enabling a one-stop approach to radiotherapy planning for these patients.

Keywords: 3D printing, lead masks

4079

Digital Poster Assessing the Feasibility of Cone Beam CT Soft Tissue Matching to the Urethra during Prostate SBRT Joanne Mitchell 1,2 , Donna Burns- Pollack 1 , Fiona Dee 1 , Joanne Matheson 1 , Duncan McLaren 1,3 , William Nailon 1,4 1 Edinburgh Cancer Centre, NHS Lothian, Edinburgh, United Kingdom. 2 College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, United Kingdom. 3 Institute of Genetic & Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom. 4 School of Engineering, University of Edinburgh, Edinburgh, United Kingdom